EVLO - エベロ・バイオサイエンシズ (Evelo Biosciences Inc.) エベロ・バイオサイエンシズ

 EVLOのチャート


 EVLOの企業情報

symbol EVLO
会社名 Evelo Biosciences Inc (エベロ・バイオサイエンシズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Evelo Biosciences Inc. is engaged in developing therapies designed to act on gut-body network. The Company develops monoclonal microbes that are orally-delivered compositions of specific strains of naturally occurring microbes derived from a single clone. Its principal product candidates include EDP1066 EDP1815 and EDP1503 that are in the pre-clinical development stage. EDP1066 and EDP1815 are monoclonal microbial product candidates that are developed to treat inflammatory diseases that include psoriasis atopic dermatitis rheumatoid arthritis and ulcerative colitis. EDP1503 is the Company's product candidate developed under oncology portfolio to treat diseases such as colorectal cancer renal cell carcinoma and melanoma among others.   エベロ・バイオサイエンシズは米国のバイオ医薬品企業。主にマイクロバイオ―ムによる、がん、自己免疫および炎症性疾患に対する免疫療法の開発に従事する。同社は、がん治療のためのオンコマイシンを開発。また、アトピ―性皮膚炎、関節リウマチ、潰瘍性大腸炎、結腸直腸がん、腎細胞がん、メラノ―マなどの免疫療法に焦点を当てる。本社所在地はマサチュ―セッツ州ケンブリッジ。   Evelo Biosciences is a clinical stage biotechnology company developing orally delivered product candidates that are designed to act on the small intestinal axis, SINTAX™, with systemic therapeutic effects. SINTAX plays a central role in governing the immune, metabolic, and neurological systems. The Company's first product candidates are pharmaceutical preparations of single strains of microbes selected for the potential to offer defined pharmacological properties. Evelo's therapies have the potential to be effective, safe, and affordable medicines to improve the lives of people with inflammatory diseases and cancer.
本社所在地 620 Memorial Drive Suite 200 Cambridge MA 02139 USA
代表者氏名 Noubar B. Afeyan Noubar B. Afeyan
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 617-870-8281
設立年月日 41760
市場名 NASDAQ National Market System
ipoyear 2018年
従業員数 59人
url www.evelobio.com
nasdaq_url https://www.nasdaq.com/symbol/evlo
adr_tso
EBITDA EBITDA(百万ドル) ー
終値(lastsale) 11.65
時価総額(marketcap) 369789663.3
時価総額 時価総額(百万ドル) 360.26720
売上高 売上高(百万ドル) --
企業価値(EV) 企業価値(EV)(百万ドル) 196.11820
当期純利益 当期純利益(百万ドル) --
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Evelo Biosciences Inc revenues was not reported. Net loss applicable to common stockholders increased from $14.4M to $29.6M. Higher net loss reflects Research and development - Balancing increase of 96% to $16.3M (expense) General and administrative - Balancing increase from $2.6M to $6.4M (expense) Stock-based Compensation in SGA increase from $256K to $1.9M (expense).

 EVLOのテクニカル分析


 EVLOのニュース

   Evelo Biosciences: Hope After Dilution? (NASDAQ:EVLO)  2022/06/06 23:57:29 Seeking Alpha
Today, we put Evelo Biosciences in the spotlight for the first time. The company has several potential catalysts on the horizon. Read more on EVLO stock here.
   What Analysts Were Expecting After Evelo Biosciences Inc. (NASDAQ: EVLO) fell -5.99%  2022/06/04 16:00:00 Stocks Register
Evelo Biosciences Inc. (NASDAQ:EVLO) shares, rose in value on Friday, 06/03/22, with the stock price down by -5.99% to the previous day’s close as strong demand from buyers drove the stock to $2.51. Actively observing the price movement in the last trading, the stock closed the session at $2.67, falling within a range of $2.48 … What Analysts Were Expecting After Evelo Biosciences Inc. (NASDAQ: EVLO) fell -5.99% Read More »
   Thinking about buying stock in Evelo Biosciences, General Electric, Lucid Group, Ford Motor, or Mullen Automotive?  2022/06/02 14:35:00 Benzinga
NEW YORK , June 2, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for EVLO, GE, LCID, F, and MULN. … Full story available on Benzinga.com
   Insiders Buy More Than $41M Of 2 Penny Stocks  2022/06/02 12:19:54 Benzinga
US crude oil futures traded lower this morning on Thursday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company''s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga''s insider transactions platform.3 Evelo Biosciences The Trade: Evelo Biosciences, Inc. (NASDAQ: … Full story available on Benzinga.com
   GRPN, GNCA and LAB among mid-day movers  2022/05/25 16:49:22 Seeking Alpha
Gainers: BlackSky Technology BKSY +93%.StoneMor STON +51%.Genocea Biosciences (GNCA) +35%.Hoegh LNG Partners HMLP +31%.Caleres CAL +27%.Evelo Biosciences EVLO +20%.Spire Global…
   What Analysts Were Expecting After Evelo Biosciences Inc. (NASDAQ: EVLO) fell -5.99%  2022/06/04 16:00:00 Stocks Register
Evelo Biosciences Inc. (NASDAQ:EVLO) shares, rose in value on Friday, 06/03/22, with the stock price down by -5.99% to the previous day’s close as strong demand from buyers drove the stock to $2.51. Actively observing the price movement in the last trading, the stock closed the session at $2.67, falling within a range of $2.48 … What Analysts Were Expecting After Evelo Biosciences Inc. (NASDAQ: EVLO) fell -5.99% Read More »
   Thinking about buying stock in Evelo Biosciences, General Electric, Lucid Group, Ford Motor, or Mullen Automotive?  2022/06/02 14:35:00 Benzinga
NEW YORK , June 2, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for EVLO, GE, LCID, F, and MULN. … Full story available on Benzinga.com
   Insiders Buy More Than $41M Of 2 Penny Stocks  2022/06/02 12:19:54 Benzinga
US crude oil futures traded lower this morning on Thursday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company''s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga''s insider transactions platform.3 Evelo Biosciences The Trade: Evelo Biosciences, Inc. (NASDAQ: … Full story available on Benzinga.com
   GRPN, GNCA and LAB among mid-day movers  2022/05/25 16:49:22 Seeking Alpha
Gainers: BlackSky Technology BKSY +93%.StoneMor STON +51%.Genocea Biosciences (GNCA) +35%.Hoegh LNG Partners HMLP +31%.Caleres CAL +27%.Evelo Biosciences EVLO +20%.Spire Global…
   Elevation Oncology, Cue Biopharma top healthcare gainers, Verrica, PMV lead losers'' pack  2022/05/25 14:04:40 Seeking Alpha
Elevation Oncology ELEV +20%. Cue Biopharma (CUE) +14%. Evelo Biosciences EVLO +13%. Verrica Pharmaceuticals VRCA -58%. PMV Pharmaceuticals (PMVP) -10%.
   GRPN, GNCA and LAB among mid-day movers  2022/05/25 16:49:22 Seeking Alpha
Gainers: BlackSky Technology BKSY +93%.StoneMor STON +51%.Genocea Biosciences (GNCA) +35%.Hoegh LNG Partners HMLP +31%.Caleres CAL +27%.Evelo Biosciences EVLO +20%.Spire Global…
   Elevation Oncology, Cue Biopharma top healthcare gainers, Verrica, PMV lead losers'' pack  2022/05/25 14:04:40 Seeking Alpha
Elevation Oncology ELEV +20%. Cue Biopharma (CUE) +14%. Evelo Biosciences EVLO +13%. Verrica Pharmaceuticals VRCA -58%. PMV Pharmaceuticals (PMVP) -10%.
   Evelo Biosciences agrees over $79.2M direct offering of shares  2022/05/25 12:52:23 Seeking Alpha
Evelo Biosciences (EVLO) entered into a securities purchase agreement with investors over direct offering of 54,246,358 shares at $1.46 per share.
   Evelo Biosciences Announces $79.2 Million Registered Direct Offering of Common Stock  2022/05/25 12:37:00 GlobeNewswire
CAMBRIDGE, Mass., May 25, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced that it has entered into a securities purchase agreement with investors in a registered direct offering of 54,246,358 shares of common stock (the “Shares”) at a purchase price of $1.46 per share, resulting in gross proceeds of $79.2 million. The offering is being led by Evelo’s founder, Flagship Pioneering, with participation from other new and existing investors.
   CORRECTION: Evelo Biosciences Announces First Quarter 2022 Financial Results and Business Highlights  2022/05/12 14:47:00 GlobeNewswire
CAMBRIDGE, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline on Thursday, May 12 by Evelo Biosciences, Inc. (Nasdaq: EVLO), please note that in the first sentence of the First Quarter 2022 Financial Results (Unaudited) section, the dates should be “As of March 31, 2022, cash and cash equivalents were $39.6 million, as compared to cash and cash equivalents of $68.4 million as of December 31, 2021,” not December 31, 2021 and March 31, 2021. The corrected release follows:

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 エベロ・バイオサイエンシズ EVLO Evelo Biosciences Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)